Daicel (4202) AI Stock Analysis

• Market Cap: $357.65B
• Dividend Yield: 4.46%
• Average Volume (3M): 536.76K
• Price to Earnings (P/E): 8.5
• Beta (1Y): 1.02
• Revenue Growth: 1.29%
• EPS Growth: -22.20%
• Country: JP
• Employees: 11,134
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals - Specialty
• EPS (TTM): 36.29
• Shares Outstanding: 266,942,700
• 10 Day Avg. Volume: 480,400
• 30 Day Avg. Volume: 536,760
• PEG Ratio: -0.88
• Price to Book (P/B): 0.98
• Price to Sales (P/S): 0.60
• P/FCF Ratio: 15.09
• Enterprise Value/Market Cap: 1.59
• Enterprise Value/Revenue: 0.99
• Enterprise Value/Gross Profit: 3.46
• Enterprise Value/Ebitda: 7.21
• 1Y Price Target: $1,337.55
• Price Target Upside: -0.63% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 77 Outperform
• Price Target: ¥1,505.00 ▲(11.81% Upside)

Daicel's strong financial performance and attractive valuation are the most significant factors contributing to its score. The company's consistent revenue growth, healthy profit margins, and improved cash flow generation enhance its financial stability. The stock's valuation is appealing with a low P/E ratio and high dividend yield. However, technical indicators suggest potential short-term weakness, slightly offsetting the overall positive outlook.

Daicel Business Overview & Revenue Model

Company Description

Daicel Corporation manufactures and sells cellulosic derivatives, organic chemicals, plastics, pyrotechnic devices, and other products in Japan, Asia, North America, and Europe. It operates through Medical/Healthcare, Smart, Safety, Materials, Engineering Plastics, and Others segments. The company offers 1,3-Butylene glycol, polyglycerin, and thickener for cosmetics; natural health food materials and supplements; and chiral and achiral columns, chiral reagents, bio reagents, and DNA and RNA-based probes, as well as analytical/purification/synthesis/formulation services, and analytical tools services for pharmaceuticals. It also provides triacetylcellulose and films for display market; solvent for electronic materials, polymers for resist, and semiconductor process cleaning agents; and optical parts and lens units, silver nanoparticle inks, and organic semiconductor devices for visualization technology. In addition, the company offers inflators for air bags and pyro-fuse for automotive market, as well as safety device for non-mobility products; acetic acid and derivatives, cellulose acetate, acetate tow, and other raw materials for resins and inks, and solvents for paints; and cycloaliphatic epoxies, caprolactone, ketene derivatives, alkylamines, and other raw materials for electrical materials and coatings. Further, it provides a range of plastics, such as engineering plastics, plastic compound products, functional sheets, formed trays, and packaging films for engineering plastics segment. Additionally, the company manufactures and distributes water treatment systems and diffusers for a range of industrial applications. Its products are used in transportation, electronics, medical care, personal care, everyday life, and environment and energy applications. The company was formerly known as Daicel Chemical Industries, Ltd. and changed its name to Daicel Corporation in October 2011. Daicel Corporation was incorporated in 1919 and headquartered in Osaka, Japan.

How the Company Makes Money

Daicel generates revenue through several key streams, primarily from the manufacturing and sale of its chemical products and materials. The company has a strong presence in the automotive sector, providing essential components such as airbags and safety systems, which are critical for vehicle manufacturers. Additionally, Daicel earns revenue from its pharmaceutical business, supplying active pharmaceutical ingredients (APIs) and excipients for drug formulation. The company also benefits from partnerships with major automotive and electronics firms, enhancing its market reach and enabling collaborative innovations. Factors contributing to its earnings include global demand for safety products, advancements in healthcare technologies, and the growing emphasis on environmentally friendly materials in various applications.

Daicel Financial Statement Overview

Summary

Daicel presents a sound financial standing with consistent revenue growth and healthy profit margins. The balance sheet is solid, though maintaining debt levels is crucial. Cash flow generation has improved significantly, enhancing liquidity and financial flexibility.

Income Statement

Daicel shows strong financial performance with a consistent increase in total revenue over the years, reaching 586.5 billion JPY in 2025. The gross profit margin has remained robust, consistently above 27%. The net profit margin, while slightly fluctuating, is solid at 8.4% for 2025. Revenue growth rate from 2024 to 2025 is 5.1%, indicating steady growth. EBIT and EBITDA margins are healthy, suggesting efficient operating performance.

Balance Sheet

The balance sheet reflects a stable financial position with a debt-to-equity ratio at approximately 0.78, indicating moderate leverage. The equity ratio is 44.2%, reflecting a strong equity base. Return on equity (ROE) stands at 13.7% for 2025, showing efficient utilization of equity to generate profits. However, the high level of total debt at 280.9 billion JPY poses some risk if not managed properly.

Cash Flow

Daicel demonstrates positive cash flow trends, with free cash flow growing significantly from 2024 to 2025, marking a 211.7% increase. The operating cash flow to net income ratio is 1.89, indicating strong cash conversion efficiency. The free cash flow to net income ratio at 0.47 suggests adequate cash generation relative to earnings, although there is room for improvement.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	576.33B	586.53B	558.06B	538.03B	467.94B	393.57B
Gross Profit	164.16B	164.75B	159.28B	145.81B	138.61B	111.43B
EBITDA	78.79B	108.86B	111.40B	79.08B	75.84B	61.01B
Net Income	55.67B	49.48B	55.83B	40.68B	31.25B	19.71B
Balance Sheet
Total Assets	861.56B	813.83B	839.17B	765.61B	698.84B	640.38B
Cash, Cash Equivalents and Short-Term Investments	78.86B	65.14B	73.18B	93.84B	90.53B	91.54B
Total Debt	309.90B	280.92B	299.79B	317.83B	280.50B	267.60B
Total Liabilities	466.04B	438.79B	464.31B	455.17B	419.29B	395.38B
Stockholders Equity	379.17B	359.99B	358.90B	295.21B	272.02B	237.85B
Cash Flow
Free Cash Flow	0.00	23.44B	7.52B	-25.08B	-4.48B	21.08B
Operating Cash Flow	0.00	93.41B	76.73B	26.85B	42.99B	57.87B
Investing Cash Flow	0.00	-47.87B	-55.37B	-44.09B	-46.53B	-34.22B
Financing Cash Flow	0.00	-48.85B	-52.37B	19.96B	-5.45B	-17.05B

Daicel Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1346.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4202, the sentiment is Positive. The current price of 1346 is below the 20-day moving average (MA) of 1351.33, above the 50-day MA of 1339.68, and above the 200-day MA of 1259.75, indicating a neutral trend. The MACD of -0.98 indicates Positive momentum. The RSI at 50.46 is Neutral, neither overbought nor oversold. The STOCH value of 46.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4202.

Daicel Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4202	77 Outperform	$357.65B	8.50	11.71%	4.46%	1.29%	-22.20%
4205	72 Outperform	$321.53B	12.87	7.18%	4.29%	5.34%	-19.93%
4182	71 Outperform	$551.62B	13.32	6.42%	3.53%	-6.27%	40.98%
4088	69 Neutral	$501.97B	10.07	10.06%	3.07%	4.35%	7.88%
4203	68 Neutral	¥426.17B	22.23	6.78%	1.92%	4.13%	-11.82%
4183	62 Neutral	$694.75B	45.95	1.78%	4.12%	-0.91%	-74.07%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%

Daicel Corporate Events

Daicel Reports Decline in Q1 2025 Financial Results but Maintains Year-End Forecast

Daicel Corporation reported a decline in its financial performance for the three months ended June 30, 2025, with net sales decreasing by 4.3% and profit attributable to owners of the parent dropping by 40.6% compared to the previous year. Despite the downturn, the company maintains its forecast for the fiscal year ending March 31, 2026, expecting a slight increase in net sales and a recovery in profits, indicating a strategic focus on stabilizing its financial position.

The most recent analyst rating on (JP:4202) stock is a Hold with a Yen1400.00 price target. To see the full list of analyst forecasts on Daicel stock, see the JP:4202 Stock Forecast page.

Daicel Introduces Restricted Stock Incentive Plan to Boost Employee Engagement

Daicel Corporation has announced the implementation of a Restricted Stock Incentive Plan aimed at enhancing employee engagement and aligning their interests with the company’s long-term goals. This initiative is part of Daicel’s strategy to increase corporate value and promote value sharing with shareholders, reflecting its commitment to sustainable growth and employee welfare.

The most recent analyst rating on (JP:4202) stock is a Hold with a Yen1400.00 price target. To see the full list of analyst forecasts on Daicel stock, see the JP:4202 Stock Forecast page.

Daicel Corporation Announces Treasury Stock Disposal for Compensation Plan

Daicel Corporation has announced the disposal of treasury stock as part of its Restricted Stock Compensation Plan, aimed at aligning the interests of its directors and executive officers with those of shareholders. This move is expected to enhance corporate value in the medium to long term by motivating key personnel to contribute more effectively to the company’s growth.

The most recent analyst rating on (JP:4202) stock is a Hold with a Yen1400.00 price target. To see the full list of analyst forecasts on Daicel stock, see the JP:4202 Stock Forecast page.

Daicel Corporation Corrects Financial Results for FY 2025

Daicel Corporation announced corrections to its consolidated financial results for the fiscal year ended March 31, 2025. The corrections pertain to errors found in the investment in equity method investees under the segment information of the financial statements. These adjustments are crucial for accurate financial reporting and may impact stakeholders’ understanding of the company’s financial health.

The most recent analyst rating on (JP:4202) stock is a Buy with a Yen2040.00 price target. To see the full list of analyst forecasts on Daicel stock, see the JP:4202 Stock Forecast page.

Daicel Corporation Corrects Financial Results for FY 2024

Daicel Corporation announced corrections to its consolidated financial results for the fiscal year ended March 31, 2024. The corrections pertain to errors found in the ‘Investment in equity method investees’ under segment information, which have been rectified to ensure accurate financial reporting. This announcement underscores Daicel’s commitment to transparency and accuracy in its financial disclosures, which is crucial for maintaining stakeholder trust and ensuring proper market positioning.

The most recent analyst rating on (JP:4202) stock is a Buy with a Yen2040.00 price target. To see the full list of analyst forecasts on Daicel stock, see the JP:4202 Stock Forecast page.

Daicel Corporation Proposes Amendments to Enhance Business Alignment and Management Flexibility

Daicel Corporation announced proposed amendments to its Articles of Incorporation to better align with its current business operations and enhance flexibility in management. These changes aim to allow more directors, including outside directors, to chair meetings, reflecting a strategic shift to adapt to a dynamic business environment.

The most recent analyst rating on (JP:4202) stock is a Buy with a Yen2040.00 price target. To see the full list of analyst forecasts on Daicel stock, see the JP:4202 Stock Forecast page.

Daicel Corporation Announces Cancellation of 10 Million Treasury Shares

Daicel Corporation has announced its decision to cancel 10 million treasury shares, which constitutes 3.61% of its total shares before cancellation. This move, resolved at a Board of Directors meeting, is expected to impact the company’s share structure by reducing the total number of shares issued to 266,942,682, potentially affecting shareholder value and market perception.

The most recent analyst rating on (JP:4202) stock is a Buy with a Yen2040.00 price target. To see the full list of analyst forecasts on Daicel stock, see the JP:4202 Stock Forecast page.

Daicel Corporation Reports Increased Sales but Declining Profits for FY2025

Daicel Corporation reported its consolidated financial results for the year ending March 31, 2025, showing a 5.1% increase in net sales to 586,531 million yen. However, the company experienced declines in operating profit, ordinary profit, and profit attributable to owners of the parent, with decreases of 2.2%, 8.9%, and 11.4% respectively. The company also announced an increase in annual cash dividends per share from 50 yen to 60 yen, reflecting a higher dividend payout ratio. Despite the challenges in profits, Daicel’s financial position remains stable with a slight improvement in capital adequacy ratio, indicating resilience in its operations.

The most recent analyst rating on (JP:4202) stock is a Buy with a Yen2040.00 price target. To see the full list of analyst forecasts on Daicel stock, see the JP:4202 Stock Forecast page.